Plus Therapeutics regains Nasdaq compliance
Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company has regained compliance with the exchange’s minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Plus Therapeutics, Inc. reports that Nasdaq has confirmed the company has regained compliance with the exchange’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq found that, from April 6 to April 17, 2026, the closing bid price of the company’s common stock was at or above $1.00 per share.
This followed a one-for-twenty-five reverse split of the company’s common stock, which became effective on April 2, 2026. The company issued a press release on April 21, 2026 announcing the compliance confirmation and noting that Nasdaq has advised the matter is now closed.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Reverse split ratio: 1-for-25
Minimum bid threshold: $1.00 per share
Compliance measurement period: 10 consecutive business days
+2 more
5 metrics
Reverse split ratio
1-for-25
Reverse split of common stock effective April 2, 2026
Minimum bid threshold
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) requirement
Compliance measurement period
10 consecutive business days
From April 6, 2026 to April 17, 2026
Compliance confirmation date
April 20, 2026
Nasdaq Notification Letter date
Press release date
April 21, 2026
Company announcement of Nasdaq compliance
Key Terms
minimum bid price requirement, Nasdaq Listing Rule 5550(a)(2), one-for-twenty-five reverse split, clinical-stage pharmaceutical company, +2 more
6 terms
minimum bid price requirement financial
"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) financial
"minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"
one-for-twenty-five reverse split financial
"following the implementation of a one-for-twenty-five reverse split of the Company’s common stock"
clinical-stage pharmaceutical company financial
"Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics"
leptomeningeal metastases medical
"lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM)"
Leptomeningeal metastases occur when cancer cells spread to the thin layers of tissue covering the brain and spinal cord, similar to how weeds can invade the surface layer of soil. This condition often indicates advanced disease and can lead to serious neurological problems. For investors, the presence of such metastases may signal challenges in treatment options and can impact the outlook for related healthcare companies or research developments.
recurrent glioblastoma medical
"lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM)"
Recurrent glioblastoma is a form of aggressive brain cancer that has returned or progressed after initial treatment, such as surgery, radiation or chemotherapy. It matters to investors because it represents a high unmet medical need with limited treatment options, so successful new therapies can change patient outcomes, command premium prices, and drive clinical, regulatory and commercial value—while failures carry significant clinical and financial risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Plus Therapeutics (PSTV) announce in this 8-K filing?
Plus Therapeutics announced that Nasdaq confirmed the company has regained compliance with its minimum bid price requirement. Nasdaq determined the stock’s closing bid met the $1.00 per share threshold for ten consecutive business days, so the listing compliance matter is now considered closed.
How did Plus Therapeutics (PSTV) regain Nasdaq minimum bid price compliance?
Plus Therapeutics regained compliance after a one-for-twenty-five reverse stock split became effective on April 2, 2026. Following the split, Nasdaq observed the company’s shares closing at or above $1.00 per share for ten straight business days, satisfying Listing Rule 5550(a)(2).
What specific Nasdaq rule now applies to Plus Therapeutics (PSTV)?
Plus Therapeutics is now in compliance with Nasdaq Listing Rule 5550(a)(2), which sets the minimum bid price requirement. Nasdaq confirmed that, between April 6 and April 17, 2026, the company’s common stock closed at or above $1.00 per share for ten consecutive business days.
When did Plus Therapeutics’ reverse stock split take effect?
The one-for-twenty-five reverse split of Plus Therapeutics’ common stock became effective on April 2, 2026. This corporate action reduced the number of outstanding shares while proportionally increasing the share price, helping the stock meet Nasdaq’s $1.00 minimum bid price requirement.
What did Nasdaq communicate to Plus Therapeutics (PSTV) about the bid price issue?
Nasdaq notified Plus Therapeutics that the company has regained compliance with the minimum bid price rule and that the matter is now closed. This followed a review showing the closing bid price stayed at or above $1.00 per share for ten consecutive business days in April 2026.
What is Plus Therapeutics’ business focus mentioned in the disclosure?
Plus Therapeutics is described as a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat central nervous system cancers. Its lead programs focus on leptomeningeal metastases and recurrent glioblastoma, using image-guided local beta radiation and targeted drug delivery approaches.
AI-generated analysis. How Rhea-AI works. Not financial advice.
